NCT01505062 - Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2012

Primary Completion Date

August 16, 2019

Study Completion Date

August 16, 2019

Conditions

Usher SyndromeRetinitis Pigmentosa

Interventions

DRUG

SAR421869

"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"

Trial Locations (2)

75012

Investigational Site Number 250001, Paris

97239-3098

Investigational Site Number 840001, Portland